$10.60+0.14 (+1.34%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Bioventus (BVS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 0.9% in FY25, net margin 4.0%, and free cash flow (~$72.1M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+51.6%) and Capex step-up ($2.6M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼0.9%
568.1
FY21→FY25CAGR +7.2%/yr
Net income ($M)—
22.7
one-off year: see footnoteCAGR +4.1%/yr
Free cash flow ($M)▲90.8%
72.1
capex stepped upCAGR +66.1%/yr
Diluted EPS—
0.33
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+51.6%
45.5mn → 68.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$2.6M
▲155% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
4¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 70.3% → 68.3%. Net margin 4.0% is above the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 585,639.0 | 568,087.0 | 573,280.0 | 512,345.0 | 512,117.0 | 430,898.0 | ▼0.9% | +7.2% |
Cost of revenue | 183,294.0 | 179,930.0 | 185,054.0 | 184,152.0 | 181,037.0 | 128,192.0 | ▼2.8% | +8.8% |
Gross profit | 402,345.0 | 388,157.0 | 388,226.0 | 328,193.0 | 331,080.0 | 302,706.0 | ▼0.0% | +6.4% |
Research & development | 12,082.0 | 12,113.0 | 13,951.0 | 13,446.0 | 23,854.0 | 19,039.0 | ▼13.2% | −10.7% |
Selling, general & admin | 326,767.0 | 314,026.0 | 343,798.0 | 303,879.0 | 332,134.0 | 254,253.0 | ▼8.7% | +5.4% |
Total operating expenses | 345,616.0 | 334,182.0 | 403,421.0 | 409,918.0 | 498,314.0 | 290,645.0 | ▼17.2% | +3.6% |
Operating incomefeeds ROC rank | 56,729.0 | 53,975.0 | −15,195.0 | −81,725.0 | −167,234.0 | 12,061.0 | — | +45.4% |
Other income, net | −16,603.0 | −28,266.0 | −37,147.0 | −39,386.0 | −21,791.0 | −2,573.0 | — | — |
Pretax income | 40,126.0 | 25,709.0 | −52,342.0 | −121,111.0 | −189,025.0 | 9,488.0 | — | +28.3% |
Income tax | −24,202.0 | −1,565.0 | −5,293.0 | 85.0 | −44,374.0 | −1,966.0 | ▲70.4% | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 57,296.0 | 22,732.0 | −36,125.0 | −156,230.0 | −158,704.0 | 19,375.0 | — | +4.1% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.80 | 0.33 | −0.56 | −2.49 | −2.59 | −0.15 | — | — |
Diluted shares (mn) | 72.49 | 68.91 | 64.55 | 62.65 | 61.39 | 45.47 | ▲6.8% | +11.0% |
| Margins | ||||||||
Gross margin54th pct in Healthcare | 68.7% | 68.3% | 67.7% | 64.1% | 64.6% | 70.3% | ▲0.6pp | −1.9pp |
Operating margin | 9.7% | 9.5% | −2.7% | −16.0% | −32.7% | 2.8% | ▲12.2pp | +6.7pp |
Net margin67th pct in Healthcare | 9.8% | 4.0% | −6.3% | −30.5% | −31.0% | 4.5% | ▲10.3pp | −0.5pp |
† TTM = trailing four quarters through 2026-09-26.FY21 effective tax rate was −21% vs a −0% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 23% vs a −0% norm for this window, likely a one-time item; see the filing.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Bioventus' revenue last fiscal year?
Bioventus reported revenue of $568.1M in fiscal 2025, down 0.9% from fiscal 2024.
What was Bioventus' net income?
Bioventus reported net income of $22.7M in fiscal 2025, a net margin of 4.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

